Utilizing our proprietary T cell engager (XPAT) and cytokine (XPAC) platforms, we are advancing a pipeline of novel prodrugs that are selectively activated in the tumor microenvironment. Both platforms leverage our Pro-XTEN technology, which has been clinically validated to extend half-life with low immunogenicity, to generate prodrugs targeting a spectrum of solid tumors.

Amunix Pipeline graphic